The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of ...

Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.